Rodos Biotarget
Biopharmaceutical targeting platform
While Rodos BioTarget focuses on the development of novel therapeutic approaches addressing infectious and autoimmune diseases as well as cancers via immune cell-specific targeting.
Rodos BioTarget is already generating revenues, its first TargoSphere product is facing clinical trials and will transform the business to a product-based revenue model.
Balmung Capital participated in the EUR 350,000 fundraising in 2016.
Summary
Investment date: 2016
Total capital commitment: EUR 350,000
Website: http://www.biotargeting.eu/
Status: current